Position in SUPN
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$21,078,610
+$6,834,863 QoQ
Shares Held
453,206
+64.5% QoQ
Ownership
0.780%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#29
of 331 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SUPN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Aberdeen Group plc holds $220,070,795 across 11 Drug Manufacturers - Specialty & Generic names. SUPN ranks #5 (9.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
919,823 | $66,098,479 | |
| 2 | BCRX |
Biocryst Pharmaceuticals Inc
|
5,310,871 | $53,108,710 | |
| 3 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
403,485 | $25,802,865 | |
| 4 | ANIP |
Ani Pharmaceuticals Inc
|
271,760 | $22,496,292 | |
| 5 | SUPN |
Supernus Pharmaceuticals, Inc.
This page
|
453,206 | $21,078,610 | |
| 6 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
737,670 | $13,248,553 | |
| 7 | ALKS |
Alkermes plc.
|
193,805 | $10,154,412 | |
| 8 | NBIX |
Neurocrine Biosciences Inc
|
22,955 | $3,868,835 |
All Filings in SUPN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $21,078,610 | 453,206 | Shares | Defined | 2026-07-31 | |
| 2026-03-31 | $14,243,747 | 275,561 | Shares | Defined | 2026-04-29 | |
| 2025-12-31 | $13,497,227 | 271,574 | Shares | Defined | 2026-01-16 | |
| No filing history on record for this holder in this stock. | ||||||